•
Sep 30, 2021
Tourmaline Bio Q3 2021 Earnings Report
Reported financial results and provided a business update, highlighting progress in clinical trials and pipeline advancement.
Key Takeaways
Talaris Therapeutics announced its Q3 2021 financial results, reporting a net loss of $12.9 million, or $0.32 per share. The company highlighted the initial clinical update from its Phase 3 FREEDOM-1 trial and the initiation of the Phase 2 FREEDOM-2 clinical trial.
Provided initial clinical update from Phase 3 FREEDOM-1 trial evaluating FCR001 in living donor kidney transplant patients.
Initiated Phase 2 FREEDOM-2 clinical trial for FCR001 in delayed tolerance induction patients.
Presented updated long-term follow-up data from its Phase 2 LKDT study at the 2021 American Society of Nephrology meeting (ASN).
Finished the third quarter of 2021 with $254.7 million in cash, cash equivalents and marketable securities.